TECH

Bio-Techne Corp Health Care Biological Products, (No Diagnostic Substances) S&P 500Russell 3000

$72.66Close $11.3BMarket cap $43.17 – $72.7152-week range Nov 4, 2026Next report

Highlights

Strengths

Near its high at its 52-week high

Cautions

Trend not confirmed 7 of 8 conditions · RS under 70
Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Jun 30, 2026 · filed Aug 24, 2026

Off 12-month high 0%

1wk 0.2% price change

1mo 0.3% price change

12-month return 20% market up 11% · its own up 7%

F-score 8 / 9 Exceptional

Altman Z 15.90 Low risk

P/E 62.4× price / earnings

PEG 0.41 P/E / EPS growth

P/B 5.4× price / book

Earnings yield 2.2% EBIT / enterprise value

Cheaper than 37% of the market · expensive

Revenue growth 0% year on year

EPS growth — latest quarter

Sales growth 1% latest quarter · +3 pts

ROE 9% return on equity

Free cash margin 22% $263.2M FCF

D/E 0.09 long-term debt / equity

Net debt / EBITDA -0.2× net cash

Interest cover —EBIT / interest

Piotroski tests

issued more shares
profitable on its assets
generating cash from operations
profitability improving
profits backed by cash
reduced long-term debt
short-term liquidity improved
gross margin widened
assets working harder

Repair signals

Long-term debt down 42% ($0.3B → $0.2B)

Trade setup

ATR% 0.2% $0.14 a day · 2×ATR $72.38

RS 68 / 99 vs the universe

Trend 7 / 8 RS under 70

Relative volume 0.9× vs 50-day average

Up/down volume 1.13 50 sessions

Implied move 4.9% by Jan 15, 2027 · report Nov 4, 2026

Trend template · 7 of 8

RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Revenue shrinking Revenue fell 0.4% over the year, from $1.2B to $1.2B.

Last reported Aug 12, 2026

Results reaction Aug 12, 2026-1% vs market2 sessions after results

Options $69017.4% IV · activity

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $1.2B -0.4% on FY2025

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $181.9M +148% on FY2025

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $263.2M +3% on FY2025

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 66%
Net 15%
Free cash 22%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $64.7M net cash

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 156.10m +0.2% since FY2021

	FY2021Jun 30, 2021	FY2022Jun 30, 2022	FY2023Jun 30, 2023	FY2024Jun 30, 2024	FY2025Jun 30, 2025	FY2026Jun 30, 2026
Revenue	$931.0M	$1.1B	$1.1B	$1.2B	$1.2B	$1.2B
Gross margin	68%	68%	68%	66%	65%	66%
Operating income	$237.3M	$296.6M	$298.9M	$206.7M	$102.3M	$251.9M
Net income	$140.4M	$272.1M	$285.3M	$168.1M	$73.4M	$181.9M
Net margin	15%	25%	25%	15%	6%	15%
Earnings per share	$0.87	$1.66	$1.76	$1.05	$0.46	$1.16
Free cash flow	$307.9M	$280.4M	$216.1M	$236.1M	$256.6M	$263.2M
Free cash margin	33%	25%	19%	20%	21%	22%
Cash	$199.1M	$172.6M	$180.6M	$151.8M	$162.2M	$264.7M
Long-term debt	$328.8M	$243.4M	$350.0M	$319.0M	$346.0M	$200.0M
Shareholders' equity	$1.6B	$1.7B	$2.0B	$2.1B	$1.9B	$2.1B
Shares outstanding	155.82m	156.64m	157.64m	158.22m	154.97m	156.10m

Next report

Nov 4, 2026

Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology ±4.9% $69 – $76 by Jan 15, 2027

Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology ±3.3% last 4: +0.0% · -10.2% · +1.9% · -4.8%

Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology Bigger than usual 1.5× the usual move

What options price now

Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology: Bigger 17.4% priced · 1.9% recent
Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology: Choppier

Positioning

Premium traded: $690 calls $690 · puts $0 · latest session
Puts against calls, by premium Money spent on puts divided by money spent on calls. Measured in dollars rather than contracts on purpose: counting contracts treats a hundred cheap lottery tickets as more meaningful than one large position, which is backwards. Methodology: 0.00× -0.05 over the week
Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology: calls +259 · puts +322 past week

For options traders: ATM IV 17.4% (+10.0% 1w) · 1m ÷ 3m IV 1.97 · 25Δ skew — pts · Net GEX $25.8M

Most traded contracts

No contract passed the liquidity filters this week.

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 24, 2026	Annual ↗	Jun 30, 2026	55d
May 6, 2026	Quarterly ↗	Mar 31, 2026	36d
Feb 4, 2026	Quarterly ↗	Dec 31, 2025	35d
Nov 5, 2025	Quarterly ↗	Sep 30, 2025	36d
Aug 22, 2025	Annual ↗	Jun 30, 2025	53d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Feb 6, 2025	Quarterly ↗	Dec 31, 2024	37d
Nov 5, 2024	Quarterly ↗	Sep 30, 2024	36d
Aug 22, 2024	Annual ↗	Jun 30, 2024	53d
May 6, 2024	Quarterly ↗	Mar 31, 2024	36d
Feb 7, 2024	Quarterly ↗	Dec 31, 2023	38d
Nov 7, 2023	Quarterly ↗	Sep 30, 2023	38d

Current reports

Filed	Disclosed
Sep 23, 2026	Shareholder vote · Regulation FD ↗
Sep 14, 2026	Other events ↗
Aug 12, 2026	Results · Other events ↗
Jun 26, 2026	Material agreement · Director or officer change ↗
Jun 25, 2026	Regulation FD ↗
May 6, 2026	Results · Other events ↗
Feb 11, 2026	Director or officer change · Other events ↗
Feb 4, 2026	Results · Other events ↗
Nov 5, 2025	Results · Shareholder vote · Other events ↗
Aug 6, 2025	Results · Other events ↗
May 7, 2025	Results · Other events ↗
May 6, 2025	Regulation FD ↗